Home/Filings/4/0001513900-11-000006
4//SEC Filing

COLVIN PAUL 4

Accession 0001513900-11-000006

CIK 0001003124other

Filed

Dec 5, 7:00 PM ET

Accepted

Dec 6, 9:06 AM ET

Size

28.6 KB

Accession

0001513900-11-000006

Insider Transaction Report

Form 4
Period: 2011-12-05
COLVIN PAUL
EVP--Clinical Development
Transactions
  • Disposition to Issuer

    Common Stock

    2011-12-05$33.25/sh45$1,4960 total
  • Disposition to Issuer

    Stock Options (to buy)

    2011-12-053,7530 total
    Exercise: $19.94Common Stock (3,753 underlying)
  • Disposition to Issuer

    Stock Options (to buy)

    2011-12-0516,0000 total
    Exercise: $26.64Common Stock (16,000 underlying)
  • Disposition to Issuer

    Stock Options (to buy)

    2011-12-0511,3860 total
    Exercise: $37.69Common Stock (11,386 underlying)
  • Disposition to Issuer

    Stock Options (to buy)

    2011-12-0531,0520 total
    Exercise: $37.51Common Stock (31,052 underlying)
  • Discretionary Transaction

    Common Stock

    2011-11-22$24.98/sh+20$50045 total
  • Disposition to Issuer

    Stock Options (to buy)

    2011-12-0530,0000 total
    Exercise: $27.27Common Stock (30,000 underlying)
  • Disposition to Issuer

    Stock Options (to buy)

    2011-12-0511,0410 total
    Exercise: $20.45Common Stock (11,041 underlying)
  • Disposition to Issuer

    Stock Options (to buy)

    2011-12-0515,9920 total
    Exercise: $25.74Common Stock (15,992 underlying)
  • Disposition to Issuer

    Stock Options (to buy)

    2011-12-0515,5260 total
    Exercise: $43.26Common Stock (15,526 underlying)
  • Disposition to Issuer

    Restricted Stock Units

    2011-12-0510,0000 total
    Common Stock (10,000 underlying)
Footnotes (9)
  • [F1]Includes shares acquired under the automatic dividend reinvestment provision of the Company's Employee Stock Purchase Plan.
  • [F2]Pursuant to the Agreement and Plan of Merger (the "Agreement") by and among Pharmaceutical Prodcut Development, Inc., Jaguar Holdings, LLC and Jaguar Merger Sub, Inc. dated as of October 2, 2011, on the effective date of the merger contemplated by the Agreement (the "Merger"), each of these shares of common stock was automatically converted into the right to receive $33.25.
  • [F3]The stock options were cancelled pursuant to the Agreement on the effective date of the Merger in exchange for a cash payment equal to the difference (if any ) between the exercise price of the stock options and $33.25 multiplied by the number of shares subject to such stock options less any applicable withholding taxes.
  • [F4]These options were cancelled pursuant to the Agreement on the effective date of the Merger in exchange for a cash payment equal to the difference (if any) between the exercise price of the stock options and $33.25 multiplied by the number of shares subject to such stock options less any applicable withholding taxes. The options were scheduled to vest in three equal installments on 2/25/11, 2/25/12 and 2/25/13 but vesting was accelerated due to the merger.
  • [F5]These stock options were cancelled pursuant to the Merger in exchange for a cash payment equal to the difference if any between the exercise price of the stock options and $33.25 mulitplied by the number of shares subject to such stock options less any applicable withholding taxes. The options were scheduled to vest in three equal increments on 2/23/12, 2/23/13 and 2/13/14 but vesting was accelerated due to the Merger.
  • [F6]These stock options were cancelled pursuant to the Merger in exchange for a cash payment equal to the difference if any between the exercise price of the stock options and $33.25 mulitplied by the number of shares subject to such stock options less any applicable withholding taxes. The options were scheduled to vest in three equal increments on 6/17/11, 6/17/12 and 6/17/13 but vesting was accelerated due to the Merger.
  • [F7]These stock options were cancelled pursuant to the Merger in exchange for a cash payment equal to the difference if any between the exercise price of the stock options and $33.25 mulitplied by the number of shares subject to such stock options less any applicable withholding taxes. The options were scheduled to vest in three equal increments on 2/18/10, 2/18/11 and 2/18/12 but vesting was accelerated due to the Merger.
  • [F8]These stock options were cancelled pursuant to the Merger in exchange for a cash payment equal to the difference if any between the exercise price of the stock options and $33.25 mulitplied by the number of shares subject to such stock options less any applicable withholding taxes.
  • [F9]Each restricted stock unit (RSU) represents a contingent right to receive one share of PPDI common stock. The RSUs were scheduled to vest in three equal increments on 2/23/12, 2/23/13 and 2/23/14 but became fully vested pursuant to the terms of the Agreement. The RSUs were disposed of pursuant to the terms of the Agreement in exchange for a cash payment of $33.25 per share upon the effective date of the Merger.

Issuer

PHARMACEUTICAL PRODUCT DEVELOPMENT INC

CIK 0001003124

Entity typeother

Related Parties

1
  • filerCIK 0001513900

Filing Metadata

Form type
4
Filed
Dec 5, 7:00 PM ET
Accepted
Dec 6, 9:06 AM ET
Size
28.6 KB